ArticleThe Journal of clinical investigation2020

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.

Evon Poon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.